Randomized, open-label, multicenter study examining the effects of duration of treatment of PEGASYS [peginterferon alfa-2a] in combination with daily COPEGUS [ribavirin] + amantadine in patients with chronic HCV [hepatitis C virus] after relapse to previous (Peg)IFN [interferon] + ribavirin therapy.
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2011
At a glance
- Drugs Amantadine (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TRELA
- 12 Jul 2011 Planned end date (Nov 2009) added as reported by European Clinical Trials Database.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-001207-19).
- 12 Jul 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History